Objective: To evaluate the efficacy of single administration of Huanglian Jiedu Tang and combined administration withbasic medicine for type 2 diabetes (T2D). Method: All of randomized controlled trials (RCTs) about the efficacy of single administration and combined administration of Huanglian Jiedu Tang in treating T2D were collected through CNKI

Wanfang Data

two Chinese periodical full text databases (CJDF and VIP)

Pubmed

Elseviser science Direct electronic journal

and Cochrane library. The assessment of methodological quality and data extraction of the included studies were performed independently by two reviewers

and the Meta-analysis was conducted with RevMan 5.3 software and stata SE 12.0 software. Result: A total of 12 RCTs involving 1 022 patients were included. According to meta-analysis

subgroup with single administration of Huanglian Jiedu Tang showed the reduction of HbAlc[MD=-0.04

95%CI (-0.60

-0.68)]

FPG[MD=-0.21

95%CI (-0.81

0.38)]

2hPG[MD=-0.30

95%CI (-0.98

0.37)]

and the effective rate of reducing blood sugar[OR=1.22

95%CI (0.74

2.03)]

which reached 84.8%

were equivalent to the control group without significant difference. The reduction of BMI[MD=-0.18

95%CI (-0.29

0.66)] and effective rate of loosing weight[OR=1.04

95%CI (0.61

1.78)]

which reached 74.8%

were also equivalent to the control group without significant difference; subgroup of combined administration of Huanglian Jiedu Tang showed the reduction of HbAlc[MD=0.53

95%CI (0.33

0.73)]

2hPG[MD=1.86

95%CI (1.59

2.14)]

effective rate of reducing blood sugar[OR=3.89

95%CI (2.18

6.93)]

which reached 90.8%

were significantly higher than the control group

but the reduction of FPG[MD=1.21

95%CI (-0.02

2.43)] was equivalent to the control group without significant difference. The reduction of BMI[MD=0.17

95%CI (-0.97

1.31)] and effective rate of loosing weight[OR=2.50

95%CI (0.74

8.50)]

which reached 83.3%

were also equivalent to the control group without significant difference. Conclusion: The efficacy of single administration of Huanglian Jiedu Tang for T2D is equivalent to Metformin. The combined administration of Huanglian Jiedu Tang with basic medicine for diabetes could reduce Hb1Ac and 2hPG obviously

which suggests that The combined administration of Huanglian Jiedu Tang could be beneficial for early-stage T2D with HbAlc<7.3%. However

due to the insufficiency of the included studies and the low methodology quality

the results of the system evaluation still need to be further verified by more high-quality large RCTs.